Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus
Novartis (NYSE:NVS) unit Sandoz said today that the FDA has accepted the abbreviated new drug application for its generic version of Advair Diskus.
The fluticasone propionate/salmeterol device is designed to treat asthma in patients ages 4 and older, as well as provide maintenance treatment of airflow obstruction and reduce exacerbations in patients with chronic obstructive pulmonary disease.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartiz unit Sandoz seeks FDA nod for generic Advair Diskus appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 16, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Amgen Novartis sandoz Source Type: news
Veramyst (Fluticasone Furoate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 16, 2017 Category: Drugs & Pharmacology Source Type: news
Breo Ellipta (Fluticasone Furoate and Vilanterol Inhalation Powder) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 26, 2017 Category: Drugs & Pharmacology Source Type: news
US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus
Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s … (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - May 11, 2017 Category: Pharmaceuticals Source Type: news
8 Things You Need To Know About Your Body's Energy Levels
By Hallie Levine
Your energy makeover starts now
It’s no wonder so many of us struggle with energy issues. We go, go, go from morning to night, running on little but grit and caffeine. But it doesn’t have to be that way! “The reality is, you can get a real boost by making a few simple changes,” says Nada Milosavljevic, MD, director of the integrative health program at Massachusetts General Hospital. That’s why we put together this complete guide to all-day energy: It’s packed with proven strategies that will keep you powered up as you plow through your to-do list. You’ll also learn...
Source: Healthy Living - The Huffington Post - May 4, 2017 Category: Consumer Health News Source Type: news
Teva launches AirDuo RespiClick, generic inhaled asthma therapies
Teva Pharmaceutical (NYSE:TEVA) said today that it launched the AirDuo RespiClick inhalation therapy and its authorized generic in the U.S. for asthma patients who are uncontrolled on an inhaled corticosteroid.
AirDuo RespiClick and the generic are fixed-dose combination therapies contained fluticasone propionate and salmeterol – the same active ingredients as Advair. The therapies are delivered using Teva’s breath-activated RespiClick inhaler.
Get the full story at our sister site, Drug Delivery Business News.
The post Teva launches AirDuo RespiClick, generic inhaled asthma therapies appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 20, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news
GSK Consumer Healthcare Launches FLONASE(R) Sensimist(TM) Allergy Relief Nationwide
WARREN, N.J., Feb. 8, 2017 -- (Healthcare Sales & Marketing Network) -- GSK Consumer Healthcare today announced the nationwide launch of FLONASE® Sensimist Allergy Relief (fluticasone furoate, 27.5 mcg spray), a new over-the-counter (OTC) treatment f... Biopharmaceuticals, Product Launch GlaxoSmithKline, GSK Consumer Healthcare, FLONASE, fluticasone, Sensimist (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 8, 2017 Category: Pharmaceuticals Source Type: news
AirDuo RespiClick Inhalation Powder (Fluticasone Propionate and Salmeterol) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news
ArmonAir RespiClick (Fluticasone Propionate Multidose Dry Powder Inhaler for Oral Inhalation) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 8, 2017 Category: Drugs & Pharmacology Source Type: news
Teva Announces FDA Approval of ArmonAir RespiClick (fluticasone propionate) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved ArmonAir RespiClick (fluticasone propionate inhalation powder) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 31, 2017 Category: Drugs & Pharmacology Source Type: news
Teva Announces FDA Approval of AirDuo RespiClick (fluticasone propionate and salmeterol) for Maintenance Treatment of Asthma
JERUSALEM--(BUSINESS WIRE) January 30, 2017 --Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo RespiClick (fluticasone propionate and salmeterol... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 30, 2017 Category: Drugs & Pharmacology Source Type: news
GSK and Innoviva begin Phase III Captain study of triple combination therapy to treat asthma
GlaxoSmithKline (GSK) and Innoviva have initiated a Phase III Captain study of a triple combination therapy consisting of fluticasone furoate / umeclidinium / vilanterol (FF/UMEC/VI) compared to dual combination therapy of Relvar / Breo (FF/VI) to tr … (Source: Drug Development Technology)
Source: Drug Development Technology - December 20, 2016 Category: Pharmaceuticals Source Type: news
GSK launches phase III trial for inhaled triple combination therapy
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that they launched a phase III trial evaluating the triple combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) in patients with asthma.
The companies’ triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day using GSK’s Ellipta dry powder inhaler.
Get the full story at our sister site, Drug Delivery Business News.
The post GSK launches phase III trial for inhaled triple combination the...
Source: Mass Device - December 19, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory GlaxoSmithKline plc Innoviva Source Type: news
GSK, Innoviva seek EU nod for triple combo inhaled therapy
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said last week that they filed a regulatory submission with the European Medicines Agency for the once-daily, triple-combination therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) for patients with chronic obstructive pulmonary disease. Last month, the companies submitted a new drug application for the inhaled therapy to the FDA for approval in the U.S.
The triple combination therapy is made up of 3 drugs – an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-adrenergic agonist. The treatment is delivered once a day ...
Source: Mass Device - December 5, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory AstraZeneca plc GlaxoSmithKline plc Innoviva Source Type: news
Flonase (Fluticasone Propionate Nasal Spray) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news
